BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

Biogen (NASDAQ:BIIB) was downgraded to hold from buy by Jefferies, due in part to a looming royalty cut for the multiple ...

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

What time is it?” Cheryl Miller asks her husband, John. He wants to answer, but his wife has already asked him that question ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a high estimate of $300.00 and a low estimate of $180.00. Highlighting a 8.24 ...

In a report released today, Michael Yee from Jefferies downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...

By speeding lifesaving drugs’ way to market and focusing on the underlying causes of disease, the pathway has helped save ...

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.

The firm sees a “tough setup” into 2025 for Biogen with modest Leqembi and Skyclarys US. It see a “real need” for more pipeline and “serious” business development to get investors re-engaged in the ...

Recently, Eisai and Biogen announced the approval of LEQEMBI in Mexico for early Alzheimer's treatment, following successful Phase 3 trials. This approval, along with ongoing reviews in 16 other ...

Mexican health authority approves Leqembi for the treatment of early Alzheimer’s disease: Tokyo Friday, December 6, 2024, 14:00 Hrs [IST] Eisai Co., Ltd. and Biogen Inc. announc ...